Literature DB >> 20859740

Acute but not chronic graft-versus-host disease is associated with a reduction of circulating CD4(+)CD25 (high)CD127 (low/-) regulatory T cells.

Sya N Ukena1, Jens Grosse, Eva Mischak-Weissinger, Stefanie Buchholz, Michael Stadler, Arnold Ganser, Anke Franzke.   

Abstract

Defects in central and peripheral tolerance are thought to contribute to life-threatening graft-versus-host disease (GvHD), a severe complication following allogeneic stem cell transplantation (SCT). Recent investigations have demonstrated regulatory T cells (Tregs) to suppress allogeneic immune reactions. Therefore, SCT patients with no or critically low numbers of Tregs may have an increased risk of GvHD. To address this hypothesis, we analyzed the recovery of CD4(+)CD25(high)CD127(low/-) Tregs in the peripheral blood of patients who have never developed GvHD (n = 6), patients who developed acute/chronic GvHD (n = 18), and patients who developed chronic GvHD without an earlier acute manifestation (n = 5) every 30 days for the first 6 months after peripheral blood SCT (PBSCT). The number of Tregs continuously improved in acute/chronic GvHD patients, but always remained lower than Tregs quantified in patients who never developed a GvHD. In contrast, chronic GvHD patients who did not develop acute GvHD earlier displayed significantly increased Treg cell numbers at the timepoint of chronic inflammation. These results indicate that numerically deficient Tregs following PBSCT are associated with the development of acute but not chronic GvHD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20859740     DOI: 10.1007/s00277-010-1068-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  14 in total

Review 1.  Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?

Authors:  F Lussana; M Di Ianni; A Rambaldi
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

2.  Reconstitution of regulatory T-cell subsets after allogeneic hematopoietic SCT.

Authors:  A Xhaard; H Moins-Teisserenc; M Busson; M Robin; P Ribaud; N Dhedin; S Abbes; M Carmagnat; V-D Kheav; G Maki; R Peffault de Latour; A Toubert; G Socié
Journal:  Bone Marrow Transplant       Date:  2014-05-19       Impact factor: 5.483

Review 3.  Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL.

Authors:  Michael R Verneris
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

Review 4.  Homeostatic control of regulatory T cell diversity.

Authors:  Adrian Liston; Daniel H D Gray
Journal:  Nat Rev Immunol       Date:  2014-01-31       Impact factor: 53.106

Review 5.  Therapeutic use of regulatory T cells for graft-versus-host disease.

Authors:  Shlomo Elias; Alexander Y Rudensky
Journal:  Br J Haematol       Date:  2019-08-16       Impact factor: 6.998

6.  LPS-treated bone marrow-derived dendritic cells induce immune tolerance through modulating differentiation of CD4+ regulatory T cell subpopulations mediated by 3G11 and CD127.

Authors:  Fang Zhou; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  Immunol Res       Date:  2017-06       Impact factor: 2.829

Review 7.  Mechanistic approaches for the prevention and treatment of chronic GVHD.

Authors:  Corey S Cutler; John Koreth; Jerome Ritz
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

Review 8.  Biologic markers of chronic GVHD.

Authors:  J Pidala; M Sarwal; S Roedder; S J Lee
Journal:  Bone Marrow Transplant       Date:  2013-07-22       Impact factor: 5.483

9.  Regulatory T-cell immunotherapy for allogeneic hematopoietic stem-cell transplantation.

Authors:  Matthew Horch; Vu H Nguyen
Journal:  Ther Adv Hematol       Date:  2012-02

10.  The role of regulatory T cells in the biology of graft versus host disease.

Authors:  Amy J Beres; William R Drobyski
Journal:  Front Immunol       Date:  2013-06-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.